- Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer
- Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting
- Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders
- The Collagen Receptor uPARAP in Malignant Mesothelioma: A Potential Diagnostic Marker and Therapeutic Target (2021)
- Adcendo Appoints Michael Pehl as Chief Executive Officer
No comments to show.